We provide end-to-end CDMO services for oligonucleotide APIs, from early development to commercial production.
With expertise in ASO, siRNA, aptamers, and more, we offer scalable process development, robust analytical support, and regulatory-compliant manufacturing.
Our facilities support synthesis up to 120 mmol and are backed by advanced quality control for every production stage.
We are a dedicated Oligonucleotide CDMO offering comprehensive services from early-stage development to commercial-scale API manufacturing.
Our integrated platform supports the full lifecycle of oligonucleotide therapeutics, including process development, analytical validation, and GMP production.
1. Full-Scale Manufacturing Support
From preclinical batches to commercial production, we provide end-to-end support for oligonucleotide APIs with capacity up to 120 mmol per batch.
2. Expertise in Diverse Oligo Modalities
We specialize in ASO, siRNA, aptamers, oligo conjugates, PMO, and PPMO, with strong capabilities in scaling up complex chemistries.
3. Advanced Analytical Development
Our team supports method development, tech transfer, validation, and ICH stability studies to meet global regulatory requirements.
4. Reliable Quality Management
Equipped with a state-of-the-art QC lab, we ensure rigorous testing and documentation across all stages — from raw materials to final drug substances.
5. Innovation-Driven Cost Efficiency
Continuous investment in technology enables us to improve product quality while minimizing production costs.
If you contact us(orders@sirnagen.com), we will promptly provide you with information on the experiment design and a quotation.
If you are interested in utilizing our SAMiRNA® platform, please contact us for further information.